| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma PG Richardson, E Weller, S Lonial, AJ Jakubowiak, S Jagannath, ... Blood, The Journal of the American Society of Hematology 116 (5), 679-686, 2010 | 1046 | 2010 |
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 897 | 2014 |
| Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma JF DiPersio, EA Stadtmauer, A Nademanee, INM Micallef, PJ Stiff, ... Blood, The Journal of the American Society of Hematology 113 (23), 5720-5726, 2009 | 873 | 2009 |
| Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth T Hitosugi, S Kang, MG Vander Heiden, TW Chung, S Elf, K Lythgoe, ... Science signaling 2 (97), ra73-ra73, 2009 | 841 | 2009 |
| Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial PM Voorhees, JL Kaufman, J Laubach, DW Sborov, B Reeves, ... Blood, The Journal of the American Society of Hematology 136 (8), 936-945, 2020 | 634 | 2020 |
| Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma S Kumar, JL Kaufman, C Gasparetto, J Mikhael, R Vij, B Pegourie, ... Blood, The Journal of the American Society of Hematology 130 (22), 2401-2409, 2017 | 523 | 2017 |
| Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma A Chari, A Suvannasankha, JW Fay, B Arnulf, JL Kaufman, ... Blood, The Journal of the American Society of Hematology 130 (8), 974-981, 2017 | 496 | 2017 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 443 | 2016 |
| Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma S Lonial, R Vij, JL Harousseau, T Facon, P Moreau, A Mazumder, ... Journal of clinical oncology 30 (16), 1953-1959, 2012 | 403 | 2012 |
| Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study AA Chanan-Khan, JL Kaufman, J Mehta, PG Richardson, KC Miller, ... Blood 109 (6), 2604-2606, 2007 | 348 | 2007 |
| Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an … SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, ... The Lancet Oncology 15 (13), 1503-1512, 2014 | 325 | 2014 |
| An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma R Vij, M Wang, JL Kaufman, S Lonial, AJ Jakubowiak, AK Stewart, ... Blood, The Journal of the American Society of Hematology 119 (24), 5661-5670, 2012 | 314 | 2012 |
| Triplet therapy, transplantation, and maintenance until progression in myeloma PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, ... New England Journal of Medicine 387 (2), 132-147, 2022 | 260 | 2022 |
| Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study NJ Bahlis, MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, ... Leukemia 34 (7), 1875-1884, 2020 | 249 | 2020 |
| Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma JJ Shah, EA Stadtmauer, R Abonour, AD Cohen, WI Bensinger, ... Blood, The Journal of the American Society of Hematology 126 (20), 2284-2290, 2015 | 240 | 2015 |
| Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX MA Dimopoulos, J San-Miguel, A Belch, D White, L Benboubker, G Cook, ... haematologica 103 (12), 2088, 2018 | 239 | 2018 |
| Randomized trial of lenalidomide versus observation in smoldering multiple myeloma S Lonial, S Jacobus, R Fonseca, M Weiss, S Kumar, RZ Orlowski, ... Journal of Clinical Oncology 38 (11), 1126-1137, 2020 | 237 | 2020 |
| A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma PG Richardson, W Xie, S Jagannath, A Jakubowiak, S Lonial, NS Raje, ... Blood, The Journal of the American Society of Hematology 123 (10), 1461-1469, 2014 | 229 | 2014 |
| Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients AK Nooka, JL Kaufman, S Muppidi, A Langston, LT Heffner, C Gleason, ... Leukemia 28 (3), 690-693, 2014 | 215 | 2014 |
| Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA G Palladini, E Kastritis, MS Maurer, J Zonder, MC Minnema, ... Blood, The Journal of the American Society of Hematology 136 (1), 71-80, 2020 | 209 | 2020 |
